Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as…
First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse…
December 09, 2024 12:05 ET | Source: Tessera Therapeutics In vivo proof-of-concept achieved in humanized mice and non-human primates (NHPs)…
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…